Neuraxis Inc NRXS
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2023-08-09 |
| Shares Out. | 12,380,000 |
| Website | neuraxis.com/ ↗ |
| Phone | 8885282677 |
| Employees | 24 |
| Revenue | $1.6M |
| Gross Profit | $1.4M |
| Net Income | -$1.8M |
| Free Cash Flow | -$6.1M |
| Total Assets | $8.7M |
| Total Liabilities | $3.0M |
| Equity | $5.7M |
About Neuraxis Inc
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Neuraxis Inc is a publicly traded company under the ticker symbol NRXS on the NYSE MKT LLC, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)